p.111 抽出テキスト

September 25, 2018 Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 e382

CLINICAL STATEMENTS AND GUIDELINES antibody fragments. Final report of a multicenter study. Circulation. 1990;81:1744–52. S10.7-2.	 Chan BS, Buckley NA, Digoxin-specific antibody fragments in the

treatment of digoxin toxicity. Clin Toxicol. 2014;52:824–36. S10.7-3.	 Keren A, Tzivoni D, Gavish D, et al. Etiology, warning signs and therapy of torsade de pointes. A study of 10 patients. Circulation. 1981;64:1167–74. S10.7-4.	 Tzivoni D, Banai S, Schuger C, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77:392–7. S10.7-5.	 Kannankeril P, Roden DM, Darbar D, Drug-induced long QT syndrome. Pharmacol Rev. 2010;62:760–81. S10.7-6.	 Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96:2149–54. S10.7-7.	 Yang T, Roden DM, Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse usedependence. Circulation. 1996;93:407–11. S10.7-8.	 Hellestrand KJ, Burnett PJ, Milne JR, et al. Effect of the antiarrhythmic agent flecainide acetate on acute and chronic pacing thresholds. Pacing Clin Electrophysiol. 1983;6:892–9. S10.7-9.	 Echt DS, Black JN, Barbey JT, et al. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs. Sodium channel block and action potential prolongation. Circulation. 1989;79:1106–17. S10.7-10.	 Schwartz PJ, Woosley RL, Predicting the unpredictable: druginduced QT prolongation and torsades de pointes. J Am Coll Cardiol. 2016;67:1639–50. S10.7-11.	 Hauptman PJ, Kelly RA, Digitalis. Circulation. 1999;99:1265–70. S10.7-12.	 Kelly RA, Smith TW, Recognition and management of digitalis toxicity. Am J Cardiol. 1992;69:108G–18G. S10.7-13.	 Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. Pacing Clin Electrophysiol. 2012;35:804–10. S10.7-14.	 Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines. Circulation. 2006;114:e385–484. S10.7-15.	 Behr ER, Ritchie MD, Tanaka T, et al. Genome wide analysis of druginduced torsades de pointes: lack of common variants with large effect sizes. PloS One. 2013;8:e78511. S10.7-16.	 Kaab S, Crawford DC, Sinner MF, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet. 2012;5:91–9. S10.7-17.	 Strauss DG, Vicente J, Johannesen L, et al. A common genetic variant risk score is associated with drug-induced QT prolongation and torsade de pointes risk: a pilot study. Circulation. 2017;135:1300–10. S10.7-18.	 Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105:1943–8. S10.7-19.	 Weeke P, Mosley JD, Hanna D, et al. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol. 2014;63:1430–7. S10.7-20.	 Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781–8. S10.7-21.	 Chamberlain DA, Jewitt DE, Julian DG, et al. Oral mexiletine in highrisk patients after myocardial infarction. Lancet. 1980;2:1324–7. S10.7-22.	 UK Rythmodan Multicentre Study Group Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group. Postgrad Med J. 1984;60:98–107. S10.7-23.	 Crijns HJ, Van Gelder IC, Lie KI, Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol. 1988;62:1303–6. S10.7-24.	 Alings M, Wilde A, “Brugada” syndrome: clinical data and suggested pathophysiological mechanism. Circulation. 1999;99:666–73. S10.7-25.	 Konigstein M, Rosso R, Topaz G, et al. Drug-induced Brugada

syndrome: clinical characteristics and risk factors. Heart Rhythm. 2016;13:1083–7. S10.7-26.	 Tada H, Sticherling C, Oral H, et al. Brugada syndrome mimicked

by tricyclic antidepressant overdose. J Cardiovasc Electrophysiol. 2001;12:275. S10.7-27.	 Littmann L, Monroe MH, Svenson RH, Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin Proc. 2000;75:845–9. S10.7-28.	 Brugada drugs. Available at: http://www.brugadadrugs.org. Accessed October 6, 2016. S10.7-29.	 Bajaj AK, Woosley RL, Roden DM, Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. Circulation. 1989;80:994–1002. S10.7-30.	 Myerburg RJ, Kessler KM, Cox MM, et al. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol. Circulation. 1989;80:1571–9. S10.7-31.	 Brumfield E, Bernard KR, Kabrhel C, Life-threatening flecainide overdose treated with intralipid and extracorporeal membrane oxygenation. Am J Emerg Med. 2015;33:1840–5. S10.7-32.	 Credible meds. Available at: http://www.crediblemeds.org. Accessed December 26, 2016.

10.8 Adult Congenital Heart Disease

S10.8-1.	 Diller GP, Kempny A, Liodakis E, et al. Left ventricular longitudinal function predicts life-threatening ventricular arrhythmia and death in adults with repaired tetralogy of fallot. Circulation. 2012;125:2440–6. S10.8-2.	 Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231–7. S10.8-3.	 Harrison DA, Harris L, Siu SC, et al. Sustained ventricular tachycardia in adult patients late after repair of tetralogy of Fallot. J Am Coll Cardiol. 1997;30:1368–73. S10.8-4.	 Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and function assessed by cardiac MRI predict major adverse clinical outcomes late after tetralogy of Fallot repair. Heart. 2008;94:211–6. S10.8-5.	 Koyak Z, de Groot JR, Bouma BJ, et al. Sudden cardiac death in adult congenital heart disease: can the unpredictable be foreseen? Europace. 2017;19:401–6. S10.8-6.	 Koyak Z, Harris L, de Groot JR, et al. Sudden cardiac death in adult congenital heart disease. Circulation. 2012;126:1944–54. S10.8-7.	 Adamson L, Vohra HA, Haw MP, Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function? Interact Cardiovasc Thorac Surg. 2009;9:520–7. S10.8-8.	 Deal BJ, Scagliotti D, Miller SM, et al. Electrophysiologic drug testing in symptomatic ventricular arrhythmias after repair of tetralogy of Fallot. Am J Cardiol. 1987;59:1380–5. S10.8-9.	 Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS Expert consensus statement on the recognition and management of arrhythmias in adult congenital heart disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Heart Rhythm. 2014;11:e102–65. S10.8-10.	 Sabate Rotes A, Connolly HM, Warnes CA, et al. Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol. 2015;8:110–6. S10.8-11.	 Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmonary valve replacement in adults after tetralogy of Fallot repair. Am J Cardiol. 2005;95:779–82. S10.8-12.	 Therrien J, Siu SC, Harris L, et al. Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation. 2001;103:2489–94. S10.8-13.	 Kella DK, Merchant FM, Veledar E, et al. Lesion-specific differences for implantable cardioverter defibrillator therapies in adults with congenital heart disease. Pacing Clin Electrophysiol. 2014;37:1492–8. S10.8-14.	 Koyak Z, de Groot JR, Van Gelder IC, et al. Implantable cardioverter defibrillator therapy in adults with congenital heart disease: who is at risk of shocks? Circ Arrhythm Electrophysiol. 2012;5:101–10. S10.8-15.	 Santharam S, Hudsmith L, Thorne S, et al. Long-term follow-

up of implantable cardioverter-defibrillators in adult congenital heart disease patients: indications and outcomes. Europace. 2017;19:407–13.

Downloaded from http://ahajournals.org by on October 7, 2026